| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017263436 |
| P356 | DOI | 10.1007/S11904-014-0243-7 |
| P3181 | OpenCitations bibliographic resource ID | 906770 |
| P932 | PMC publication ID | 4373591 |
| P698 | PubMed publication ID | 25761432 |
| P2093 | author name string | Raymond T. Chung | |
| Jessica L. Wisocky | |||
| Ming V. Lin | |||
| Neliswa A. Gogela | |||
| P2860 | cites work | Emerging therapies for hepatitis C | Q26853642 |
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options | Q29620126 | ||
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 | ||
| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection | Q29620338 | ||
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis | Q29620612 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives | Q33568568 | ||
| Hepatitis C: the clinical spectrum of the disease | Q33809411 | ||
| Epidemiology and natural history of hepatitis C virus infection | Q33948292 | ||
| Current and Future Therapies for Hepatitis C Virus Infection | Q34036762 | ||
| Viral hepatitis in HIV infection | Q34086980 | ||
| Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 | ||
| Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. | Q34429833 | ||
| Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review | Q34439125 | ||
| Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre | Q34451707 | ||
| Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. | Q34661893 | ||
| HCV and HIV co-infection: mechanisms and management. | Q35090634 | ||
| Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis | Q35194406 | ||
| Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis | Q37265953 | ||
| Completion of the entire hepatitis C virus life cycle in genetically humanized mice | Q37382399 | ||
| Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs | Q37619741 | ||
| Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. | Q37699395 | ||
| Anti-hepatitis C virus drugs in development | Q38005796 | ||
| Current prospects for interferon-free treatment of hepatitis C in 2012. | Q38058555 | ||
| NS5A inhibitors in the treatment of hepatitis C. | Q38097233 | ||
| HCV direct-acting antiviral agents: the best interferon-free combinations | Q38174253 | ||
| Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection | Q38175491 | ||
| Hepatitis C treatment: an incipient therapeutic revolution | Q38196524 | ||
| Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". | Q38204468 | ||
| The rapid evolution of treatment strategies for hepatitis C. | Q38204657 | ||
| Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. | Q38236179 | ||
| Hepatitis C virus infection and kidney transplantation in 2014: what's new? | Q38236820 | ||
| Recent advances on hepatitis C virus in dialysis population | Q38244600 | ||
| Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis | Q38970639 | ||
| Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. | Q38985083 | ||
| Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. | Q39424044 | ||
| Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression | Q39935106 | ||
| An interferon-free antiviral regimen for HCV after liver transplantation | Q41668021 | ||
| Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | Q42202756 | ||
| Antiviral treatment of hepatitis C. | Q42207125 | ||
| Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial | Q42211652 | ||
| ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. | Q42219325 | ||
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3. | Q42220605 | ||
| ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. | Q42220608 | ||
| ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis | Q42225140 | ||
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 | ||
| Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 | ||
| Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial | Q42251577 | ||
| Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial | Q42252016 | ||
| Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection | Q42258200 | ||
| Sofosbuvir-based interferon-free therapy for patients with HCV infection | Q42281006 | ||
| Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial | Q42992205 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q42995119 | ||
| Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis | Q43036709 | ||
| Sustained virological response to treatment in patients with chronic hepatitis C--reply | Q43484600 | ||
| Sexual behaviour and the risk of HCV infection | Q44138623 | ||
| Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study | Q46589510 | ||
| A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on | Q85608080 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q86939378 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 68-78 | |
| P577 | publication date | 2015-03-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current HIV/AIDS reports | Q26842190 |
| P1476 | title | Enhancing our understanding of current therapies for hepatitis C virus (HCV) | |
| P478 | volume | 12 |
| Q33822543 | A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2 |
| Q40905812 | Actinobacteria from Termite Mounds Show Antiviral Activity against Bovine Viral Diarrhea Virus, a Surrogate Model for Hepatitis C Virus |
| Q38547705 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions |
| Q26784234 | Chronic hepatitis C virus infection and lipoprotein metabolism |
| Q36026117 | Editorial: Recent Advances in HBV and HCV Immunology |
| Q28074783 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis |
| Q39262589 | Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials |
| Q90261320 | Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol) |
| Q27469084 | HCV-Mediated Apoptosis of Hepatocytes in Culture and Viral Pathogenesis |
| Q38520338 | Health disparities in liver disease in sub-Saharan Africa. |
| Q36083688 | Hepatitis C treatment initiation in HIV-HCV coinfected patients |
| Q45333992 | Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs |
| Q41035955 | Innate and Adaptive Immune Responses in Chronic HCV Infection |
| Q40404776 | Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. |
| Q38698008 | Sec24C-Dependent Transport of Claudin-1 Regulates Hepatitis C Virus Entry |
| Q40430075 | Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors |
Search more.